IAN COWIE | PERSONAL ACCOUNT
Here’s why I’m investing in another weight-loss drug
The Sunday Times
ILLUSTRATION BY LILY WALTERS
Just as the season of over-indulgence waddles into view, regulators on both sides of the Atlantic have approved a new weight-loss drug. As it appears to be even more effective than those produced by my top pharmaceutical share, and fifth-fattest holding, Novo-Nordisk (stock market ticker: NOVO), you might expect me to feel a bit queasy about this new rival.
Fortunately, I saw it coming and invested 2 per cent of my life savings in Eli Lilly (LLY), paying $441 per share, as reported here in July. Four months later, they have filled out nicely to trade at $594 on Friday and are now my sixth most valuable holding.
However, with so much bad news elsewhere, Mr Market seemed distracted when the UK Medicines and Healthcare
